Norwegian-Danish Procurement Deal Targets Biogen’s Spinraza
Norway and Denmark have signed an agreement for the joint procurement of medicines and have their eye on securing a lower price for Biogen’s orphan drug Spinraza.
You may also be interested in...
Biogen is reluctant to enter joint talks with Norway and Denmark over Spinraza, but the company expects that cross-country pricing and reimbursement collaboration will become a fixture.
A new joint procurement agreement between Norway and Denmark is a signal to drug companies that they will have to increasingly negotiate with more than one country in a new age of collaboration, says Amgros, the Danish medicines procurement agency.
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.